PREDICT was a Canadian, multicenter, prospective, observational study in adults naïve to onabotulinumtoxinA treatment for chronic migraine (CM). We descriptively assess health resource utilization, work productivity, and acute medication use.

OnabotulinumtoxinA (155–195 U) was administered every 12 weeks over 2 years (≤7 treatment cycles). Participants completed a 4-item health resource utilization questionnaire and 6-item Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0. Acute medication use was recorded in daily headache diaries. Treatment-emergent adverse events were recorded throughout the study.

A total of 197 participants were enrolled, and 184 received ≥1 treatment with onabotulinumtoxinA and were included in the analysis. Between baseline and the final visit, there were decreases in the percentage of participants who reported headache-related healthcare professional visit(s) (96.2% to 76.8%) and those who received headache-related diagnostic testing (37.5% to 9.9%). Reductions from baseline were also observed in the mean number of headache-related visits to an emergency room/urgent care clinic (2.5 to 1.4) and median headache-related hospital admissions (4.0 to 1.0). OnabotulinumtoxinA improved work productivity and reduced the mean (standard deviation) number of hours missed from work over a 7-day period (6.1 [9.7] to 3.0 [6.8]). Mean (standard deviation) acute medication use decreased from baseline (15.2 [7.6] to 9.1 [6.5] days). No new safety signals were identified.

Real-world evidence from PREDICT demonstrates that onabotulinumtoxinA treatment for CM in the Canadian population reduces health resource utilization and acute medication use and improves workplace productivity, supporting the long-term benefits of using onabotulinumtoxinA for CM.

The PREDICT study assessed real-world, long-term health-related quality of life in adults with chronic migraine (CM) receiving onabotulinumtoxinA.

Canadian, multicenter, prospective, observational study in adults naïve to onabotulinumtoxinA for CM. OnabotulinumtoxinA (155–195 U) was administered every 12 weeks over 2 years (≤7 treatment cycles). Primary endpoint: mean change in Migraine-Specific Quality of Life Questionnaire (MSQ) at treatment 4 (Tx4) versus baseline. Secondary endpoints: mean change in MSQ at final visit versus baseline, and headache days.

184 participants (average age 45 years; 84.8% female; 94.6% Caucasian) received ≥1 onabotulinumtoxinA treatment; 150 participants completed 4 treatments (1 year) and 123 completed all 7 treatment cycles (2 years). Mean (SD) onabotulinumtoxinA dose per treatment cycle was 171 (18) U and treatment interval was 13.2 (1.8) weeks. Baseline mean (SD) 20.9 (6.7) headache days/month decreased (Tx1: −3.5 [6.3]; Tx4: −6.5 [6.6]; p < 0.0001 versus baseline). Mean (SD) increased from baseline in MSQ at Tx4 (restrictive: 21.5 [24.3], preventive: 19.5 [24.7], emotional: 22.9 [32.9]) and the final visit (restrictive: 21.3 [23.0], preventive: 19.2 [23.7], emotional: 27.4 [30.7]), exceeding minimal important differences (all p < 0.0001). Seventy-seven (41.8%) participants reported 168 treatment-emergent adverse events (TEAEs); 38 TEAEs (12.0%) were considered treatment-related. Four (2.2%) participants reported six serious TEAEs; none were considered treatment-related. No new safety signals were identified.

Real-world evidence from PREDICT demonstrates that onabotulinumtoxinA for CM in Canada improved MSQ scores and reduced headache frequency and severity, adding to the body of evidence on the long-term safety and effectiveness of onabotulinumtoxinA for CM.

Infection with coronavirus disease 2019 (COVID-19) has become a severe public health issue worldwide. A broad amount of information related to the novel coronavirus (COVID-19) pandemic was disseminated by social media in Ethiopia. To date, there is limited evidence on the influence of social media use for COVID-19–related information on COVID-19 preventive practice. Therefore, this study aimed to assess the influence of social media use on the practice of COVID-19 preventive measures in Ethiopia.

This study used an anonymous Internet-based online cross-sectional survey using Google Forms to collect the data from the respondents from May 15 to June 17, 2020, in Ethiopia. Multivariable logistic regression was used to assess the relationship between social media use as a predictor and COVID-19 preventive practice, after adjusting for socio-demographic and risk perception of COVID-19 variables. The data were analyzed using SPSS version 21.

A total of 372 respondents have participated in the study. From 372, a total of 208 (55.9%) respondents in this study were male. Study participants who had good use of social media to get COVID-19–related information were 9.5 times more engaged in COVID-19 preventive practices compared with study participants who had poor use of social media to get COVID-19–related information (adjusted odds ratio [AOR] = 9.59; 95% confidence interval [CI]: 5.70-16.13). Also, study participants who had a high-risk perception of COVID-19 were 2.6 times more engaged in COVID-19 practices compared with study participants who had a low-risk perception of COVID-19 (AOR = 2.63; 95% CI: 1.58-4.38). Study participants who were students at the time of this study were 4 times more likely to show an adequate COVID-19 preventive practice score compared with those who had another occupational status (AOR = 4.07; 95% CI: 1.66-9.98)

Our results show that the use of social media networks can have a positive effect on the practice of preventive measures and public safety against COVID-19; high-risk perception contributed to preventive activities against COVID-19. Social networking platforms can be used by public health agencies as an important method to raise public health understanding by disseminating concise messages to targeted audiences.